Induction of Cure in Early Arthritis treated early DMARD-naïve Undiff. Arthritis (≥2 joints) w/ NSAIDs (29), MTX 15-25/wk (28), or baricitinib 4 mg/d (28) x 3 mos. Entry DAS ~ 2.4 w/ 2-3 SJC, <17%CCP+. @3 mos Bari > NSAID (DAS−0.52;p=0.01) = MTX (−0.39, p=0.09).@1yr MTX DAS https://t.co/1kKjginhKM

An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment? 🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/JvH74D2ocI https://t.co/4N1kW214Ak

HPV Vaccination in Rheumatic Diseases Dr. Bella Mehta reports on abstract OP0225 presented at the 2026 EULAR Congress meeting in London. https://t.co/PMJ7U9kASW https://t.co/aqoNl3B4Vc

20% sample of elder RA Medicare pts (2009-2022) on TNFi who either stopped or tapered TNFi found 38% sustained de-escalation, while 62% re-escalated within a medianof 164. Re-escalation was more likely in Blacks, Hispanic/other, with a lower comorbidity burden. https://t.co/rEB3VdOii2

Imaging in SpA: are we seeing a clearer picture? The diagnosis of SpA is highly dependent on imaging particularly in a young patient with chronic, inflammatory back pain. It is timely enough since there have been rapid developments in imaging techniques like MRI, Ultrasound and https://t.co/mCPwzGAEVv

US telehealth utilization rose 10.1% in 1st quarter of 2026 (5% to 5.51% medical claims). Most use in mental health conditions (52%) w/ joint/soft tissue dz at 3% overall, higher in west & NE states. 57% for outpt visits, only 7.7% for new visits. 35% for psychotherapy services. https://t.co/L8c7p3iQPL

From BiTE to TriTE: Progress of T-cell Engagers in RMDs At EULAR 2026 in London, T-cell engagers drew attention as a strategy to achieve deep B-cell depletion and drug-free remission in refractory RMDs. BiTEs offer off-the-shelf availability, reversible toxicity from short https://t.co/o8Tn77aYRg

Nature has published that Hyperglycosylation is a metabolic driver of Alzheimer’s Dz (AD) & Glucosamine (GS; taken by ~7% over 70yrs) & GS may increase hyperglycosylation. A retrosp EHR study of AD pts shows glucosamine use assoc w/ accelerated AD progression & worse survival https://t.co/bv6H9h6gAv

Long-term Cancer Risk with Targeted Therapy in SpA Dr. Antoni Chan reports on abstract OP0238 presented at EULAR 2026 in London https://t.co/f67SvKI6Vk https://t.co/fPp2H0aMoK

In the psoriasis-to-PsA transition study at EULAR 2026, which ultrasound finding best distinguished progressing from stable subclinical PsA? Test your knowledge in this week's RheumIQ quiz at https://t.co/Fnzn4UPu0n https://t.co/kV0zA7qyg7

Kyoto U. cohort study of 55 relapsing polychondritis pts (503 Pt-yrs) Rx w/ TNFi, IL-6i or none -- Crude relapse rates were 46.9/100PYs NoBio, 22.4 TNFi, & 12.5 IL-6Ri. Adjusted relapses signif lower w/ TNFi (IRR 0.4) & IL-6Ri (IRR 0.2) vs no biologic. Estimates for hospitalised https://t.co/h6IcVWjqfp

A provacative OPINION piece in The Hill asks, is "China is quietly taking control of US medicine..." Should the US & FDA facilitating, ignorning or opposing Chinas influence? Issues of transparency, manufacturing, global supply chain, outsourcing early phase RCTs, etc. https://t.co/4vveTR8UK8